Selank Peptide Research: Tuftsin-Derived Anxiolytic Mechanisms, GABAergic Modulation, and Immunoregulatory Evidence

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic tuftsin-derived heptapeptide that modulates anxiolytic and immunoregulatory pathways through indirect GABAergic allosteric modulation, BDNF upregulation, and IL-6 cytokine signaling. Over three decades of preclinical and early clinical investigation have established Selank as one of the most extensively studied anxiolytic peptides with a dual neuroimmune mechanism of action. Selank peptide research is concentrated in rodent stress and anxiety paradigms and in vitro immune assays, so the evidence base should be read as mechanistic rather than clinical.

Selank peptide research spans over three decades of investigation into a synthetic heptapeptide with dual anxiolytic and immunomodulatory properties. Developed at the Institute of Molecular Genetics (IMG) of the Russian Academy of Sciences in Moscow under the direction of Nikolai Myasoedov, Selank emerged from a research program that began in the late Soviet period during the 1980s. The peptide was designed as a stabilized analog of tuftsin, a naturally occurring tetrapeptide derived from the Fc region of immunoglobulin G, with the specific goal of extending biological half-life while preserving and expanding upon tuftsin’s immunoregulatory activity.

This article examines Selank’s molecular structure, its dual mechanism of action across GABAergic and immune pathways, the preclinical and clinical evidence base, and its significance as a research tool for investigating peptide-mediated anxiolysis without benzodiazepine-class side effects.

Molecular Structure and Design Rationale

Selank’s amino acid sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP). The first four residues (Thr-Lys-Pro-Arg) correspond to the naturally occurring tetrapeptide tuftsin, which is generated by enzymatic cleavage of the CH2 domain of the immunoglobulin G heavy chain. Native tuftsin has a biological half-life of only minutes due to rapid degradation by aminopeptidases and carboxypeptidases in circulation.

The IMG research team addressed this limitation by appending a Pro-Gly-Pro C-terminal extension, a stabilization strategy also employed in the design of Semax (an ACTH(4-10) analog). The tripeptide extension protects against enzymatic degradation while conferring conformational properties that enabled anxiolytic activity not present in the parent tuftsin molecule. This represents a significant pharmacological outcome: the stabilization modification did not merely extend half-life but introduced an entirely new category of bioactivity.

GABAergic Mechanism: Indirect Allosteric Modulation

Selank’s anxiolytic mechanism appears to operate through indirect modulation of the GABAergic system rather than direct receptor agonism. Volkova and colleagues (Frontiers in Pharmacology 2016;7:31) profiled 84 neurotransmission genes, including GABA-A receptor subunits, transporters, ion channels and dopamine and serotonin receptors, in rat frontal cortex one and three hours after Selank or GABA administration. Forty-five genes changed expression at one hour and 22 at three hours, and the changes produced by Selank correlated positively with those produced by GABA itself. The authors interpreted the overlap as evidence that one of Selank’s molecular mechanisms is allosteric modulation of the GABAergic system.

A follow-up study by Filatova and colleagues (Frontiers in Pharmacology 2017;8:89) tested the same 84-gene panel in IMR-32 neuroblastoma cells exposed to Selank, GABA, olanzapine and their combinations. Selank on its own changed none of the transcripts, but when combined with GABA it almost completely suppressed the expression changes that GABA alone produced, and in combination with olanzapine it altered the expression of more genes than olanzapine alone. The authors concluded that Selank has no direct effect on GABAergic gene expression in these cells and that its action is more likely exerted on the interaction between GABA and its receptors, which is consistent with the indirect allosteric model rather than with binding at the benzodiazepine site.

Monoaminergic and Enkephalin Interactions

Beyond GABAergic modulation, Selank research has revealed effects on enkephalin degradation and monoamine metabolism. Zozulya and colleagues (Bulletin of Experimental Biology and Medicine 2001;131:315-317) reported that Selank inhibited enzymatic hydrolysis of plasma enkephalin in a concentration-dependent manner, with an IC50 of about 15 micromolar, and was more potent than the peptidase inhibitors bacitracin and puromycin, which the authors proposed as a mechanism for stabilising endogenous opioid peptide levels. Semenova and colleagues (Eksperimental’naia i Klinicheskaia Farmakologiia 2009;72:6-8) compared Selank with its parent tuftsin in rats pretreated with the serotonin synthesis inhibitor p-chlorophenylalanine and found that Selank enhanced serotonin metabolism in the brain stem within 30 minutes while tuftsin did not. This multi-system engagement, spanning GABAergic, serotonergic and enkephalinergic pathways, distinguishes Selank from single-target anxiolytic compounds.

Immunomodulatory Activity: Tuftsin Heritage

Selank retains and extends the immunomodulatory properties of its parent molecule tuftsin. Kolomin and colleagues profiled the time course of inflammation-related gene expression after Selank administration (Molecular Immunology 2014;58:50-55), and Uchakina and colleagues described immunomodulatory effects of the peptide in patients with anxiety-asthenic disorders (Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova 2008;108:71-75). Reported immune-relevant activities include effects on interleukin-6 (IL-6) production, phagocytic activity in monocytes and macrophages, and the Th1/Th2 immune response balance. The IL-6 modulation is particularly notable: rather than acting as a simple pro-inflammatory or anti-inflammatory agent, Selank appears to normalize IL-6 signaling, increasing it when suppressed and attenuating it during excessive inflammatory states.

This dual anxiolytic-immunomodulatory profile is rare among peptide research compounds and makes Selank a valuable tool for investigating the bidirectional relationship between immune function and anxiety-like behavior, a connection increasingly recognized in neuroimmunology research.

BDNF and Neurotrophic Effects

Selank administration has been reported to regulate expression of brain-derived neurotrophic factor (BDNF) in the rat hippocampus in vivo (Inozemtseva and colleagues, Doklady Biological Sciences 2008;421:241-243), and BDNF is a critical mediator of neuronal survival, synaptic plasticity, and cognitive function. BDNF upregulation is of particular research interest because reduced BDNF levels are consistently observed in animal models of chronic stress and anxiety. By simultaneously modulating GABAergic tone and promoting neurotrophic factor expression, Selank engages complementary mechanisms that address both the acute neurochemical imbalance and the longer-term neurotrophic deficits associated with sustained anxiety states in preclinical models.

Key Research Findings: Clinical and Preclinical Evidence

The principal clinical report is by Zozulia and colleagues (Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova 2008;108:38-48), who studied 62 patients with generalized anxiety disorder and neurasthenia, comparing Selank in 30 patients against the benzodiazepine medazepam in 32, with outcomes assessed on the Hamilton, Zung and CGI scales and serum enkephalin activity measured alongside. The anxiolytic effects of the two agents were similar, and Selank additionally showed antiasthenic and psychostimulant effects. The same study found that leu-enkephalin half-life was reduced in these patients in proportion to illness duration and symptom severity, and that it increased during Selank treatment, mainly in the generalized anxiety group, which ties the clinical observation back to the enkephalinase mechanism described above.

In preclinical work, Kasian and colleagues (Behavioural Neurology 2017;2017:5091027) compared Selank and diazepam, alone and in combination, in rats with and without unpredictable chronic mild stress using the elevated plus maze. Selank alone was the most effective agent against the anxiety produced by repeated administration of the test substances themselves, whereas under chronic stress the combination of diazepam and Selank returned anxiety indicators to their pre-stress values.

The clinical evidence derives from studies conducted within the Russian regulatory framework, and Selank has not been evaluated by the FDA or the EMA. Its research value lies in the mechanistic contrast it offers to benzodiazepine-class compounds in preclinical anxiety models.

Research Summary

Selank (TKPRPGP) is a synthetic tuftsin analog carrying a Pro-Gly-Pro stabilisation extension, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. Its anxiolytic action is attributed to indirect modulation of GABAergic signalling: Selank changed the expression of dozens of neurotransmission genes in rat frontal cortex in parallel with GABA (Volkova et al., 2016) yet had no direct effect on GABAergic gene expression in IMR-32 cells, where it instead modified the response to GABA (Filatova et al., 2017). The peptide inhibits enkephalin-degrading enzymes with an IC50 near 15 micromolar (Zozulya et al., 2001), enhances brain stem serotonin metabolism in serotonin-depleted rats (Semenova et al., 2009), and regulates hippocampal BDNF expression in vivo (Inozemtseva et al., 2008). Immunomodulatory activity inherited from tuftsin has been characterised at the level of inflammation-related gene expression (Kolomin et al., 2014). The main clinical comparison, 62 patients with generalized anxiety disorder or neurasthenia, found anxiolytic efficacy similar to medazepam with additional antiasthenic effects (Zozulia et al., 2008), and a rat study found Selank alone or combined with diazepam reduced anxiety indicators under chronic mild stress (Kasian et al., 2017). No FDA or EMA evaluation has taken place.

Purity Considerations for Selank Research

Selank’s heptapeptide structure includes a proline-rich sequence that can present synthesis challenges, particularly regarding deletion sequences and incomplete couplings at the Pro-Pro junction. Researchers should verify supplier purity claims through independent third-party COA testing. At Maple Research Labs, the independent laboratory report for the current tested batch of Selank is published on the Certificates of Analysis page with its report number, lot, measured HPLC-UV purity and test date, alongside the other tested compounds and those still awaiting a certificate.

For researchers exploring Selank alongside related neuropeptides, see our research coverage of Semax and browse our full research peptide catalog. Our COA verification guide explains how to interpret HPLC and MS data. Canadian researchers can review domestic sourcing options for faster shipping and simplified procurement.

Selank’s tuftsin lineage places it in the immunopeptide family. Dihexa’s angiotensin IV lineage and HGF/c-Met activation belong to a growth-factor pathway with picomolar synaptogenic potency in preclinical models, which makes the two a useful contrast for researchers mapping neurotrophic mechanisms.

Selank’s combined anxiolytic and immunoregulatory profile makes it useful to compare with other neuropeptide systems studied in rodent stress models. Neuropeptide Y produces anxiolytic-like effects largely through Y1 receptors in the amygdala, and neuropeptide S is notable for reducing anxiety-like behaviour while increasing arousal, the opposite of the sedative profile of benzodiazepines. On the immune side, thymosin alpha-1 research offers a comparison point for short-peptide modulation of T-cell maturation and cytokine output.

For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use.

For peer-reviewed research on this topic, visit PubMed.